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Introduction. Constipation is a common adverse drug reaction. Objective. Study associations between drugs and constipation
in nursing home residents. Design. Cross-sectional study. Material and Methods. Nursing home residents above 60 years of age
were included. Demographics, diet, physical activity, activity of daily living, nutritional status, use of drugs, and diseases were
recorded. Constipation was deﬁned as functional constipation or constipation-predominant IBS according to the Rome III criteria
and/or regular use of laxatives. Drugs were classiﬁed according to the Anatomical-Therapeutic-Chemical Classiﬁcation System
(ATC), and anticholinergic eﬀect was noted. Results. In all, 79 men and 188 women with a mean age of 85.4 (SD 7.1) years were
included. The prevalence of constipation was 71.5%. Use of drugs in general, including polypharmacy, was not associated with
constipation. Reduced activity of daily living (OR = 0.71, 95% CI:0.60–0.84, P<0.001), other antidepressants (N06AX) (OR
3.08, 95% CI:1.09–8.68, P = 0.03), and benzodiazepine derivatives (N05BA) (OR = 2.80, 95% CI:1.12–7.04, P = 0.03) were
signiﬁcantly associated with constipation; drugs with markedly anticholinergic eﬀect (OR = 3.7, 95% CI:0.78–17.53, P = 0.10),
natural opium alkaloid (N02AA) (OR = 5.01, 95% CI:0.95–25.94, P = 0.06), and propionic acid derivatives (M01AE) (OR = 7.00,
95% CI:0.75–65.08, P = 0.09) showed a trend. Conclusion. In elderly with constipation, focus should be on speciﬁc groups of
drugs and nonpharmacological factors, not on drugs in general.
1.Introduction
Chronic functional constipation aﬀects 17–40% of the eld-
erly and reduces quality of life [1–4]. In nursing homes, the
prevalence of constipation is in the order of 44–74% [4–7].
Gastrointestinal symptoms including constipation are
common adverse drug reactions [8]. Drugs have been
reportedasoneofthemostimportantcausesofconstipation,
in addition to insuﬃcient intake of ﬂuid and dietary ﬁbre,
reduced activity of daily living, lack of exercise, and diseases
such as neurological and metabolic disorders [5–7, 9].
In general, the use of drugs is high in elderly in nursing
homes [10–13]. Frail elderly with chronic diseases, altered
pharmacokinetics and pharmacodynamics, and use of sev-
eral drugs with anticholinergic eﬀects and in part unknown
interactions appear to be at high risk of side eﬀects of drugs
[8, 10–12, 14–16].
This cross-sectional study aimed at ﬁnding the impact of
drugs on constipation in elderly in nursing homes.
2.MaterialandMethods
2.1. Study Design and Methods. In 2008-2009, this cross-
sectional study was performed in nursing homes in the
counties of Oppland and Hedmark, Norway. Registered
and auxiliary nurses with good knowledge of the residents
collected data from the medical records and got information
from the residents and their next of kin. A blood sample was
collected.2 Gastroenterology Research and Practice
2.2. Study Population. Residents above 60 years of age living
innursinghomesformorethan8weeksandwithoutorganic
gastrointestinal diseases that could cause constipation were
included in the study.
2.3. Variables. The following variables were recorded: age,
gender, weight, height, smoking habits, use of alcohol,
somatic and psychiatric diseases, physical activity (walking
steps/day, mobility), activity of daily living (Katz’ Activity
of Daily Living (ADL) index (score 0 (very dependent)–6
(independent)), nutritional status (Mini Nutritional Assess-
ment (MNA score 0–30: <17 malnourished; 17–23.5 at
risk of malnutrition; 24–30 normal nutritional status) [17],
diet (ﬁbre and amount and type of ﬂuid), type of food
(mashedfood/soups,breadwithoutcrust,ordinaryfood),all
use of drugs, a detailed description of the bowel function,
continence for urine and faeces, dental status, signs of dehy-
dration, and bedsore. A laboratory screen was performed.
ConstipationwasdeﬁnedaccordingtotheRomeIIIcrite-
riaforfunctionalconstipation[18]exceptforinsuﬃcientcri-
teria for irritable bowel syndrome because cognitive impair-
mentmadethisinformationunreliable,and/orregularuseof
a laxative. Drugs were measured as use of drugs (yes/no) and
the number of drugs (laxatives, dermatologicals, and topical
preparations for eyes and ears were excluded). The drugs
were grouped according to the Anatomical-Therapeutic-
Chemical Classiﬁcation System (ATC) at level four since
drugs at this level probably have common adverse drug
reactions [19]. In addition, anticholinergic eﬀect (yes/no)
was recorded as use of one or more drugs with markedly
anticholinergic eﬀect deﬁned as level 3 according to Carna-
hanetal.[20].Drugsforconstipation(ATC-classesA06)and
groups of drugs used by less than 10 residents were excluded
from all analyses.
2.4. Statistical Analysis. Associations between constipation
and the recorded variables were analyzed with Student’s t-
test, Mann-Whitney U test, Fisher’s exact test, and Chi-
square for trend. Three multivariable analyses (stepwise
backward logistics regression) were performed with consti-
pation as dependent factor and either number of drugs,
drugs with markedly anticholinergic eﬀect, or groups of
drugs at ATC-level 4 with P ≤ 0.2 in bivariate analyses as
independent variables. In addition, variables presumed to be
associatedwithconstipation(physicalactivity,intakeofﬁbre,
and ﬂuid), and other variables associated with constipation
with P ≤ 0.05 in the bivariate analyses were included in the
analyses. The cut-oﬀ point for groups of drugs was set to
P<0.2 to avoid loss of any group of drugs since this was
the primary aim of the study. The cut-oﬀ point for other
variables was P<0.05 to reduce the number of covariates
in the calculations. Since a drug is highly associated with
the disease under treatment, both the group of drugs and
the disease were included if one of them was associated with
constipation with P ≤ 0.2 in the bivariate analyses. The one
with the lowest impact on the outcome in the multivariable
analyseswasremoved.Ageandgenderweremaintainedinall
analyses, and number of drugs and the anticholinergic eﬀect
were maintained in the respective analyses, independent
of degree of signiﬁcance. Other variables were removed
one by one in the backward regression analyses until only
variables with P<0.1 remained in the equation. Foreseeable
interactions were controlled for.
Multiple imputation for missing data was performed
with all variables included in the analyses [21]. Two-sided
P values ≤ 0.05 were regarded as statistically signiﬁcant
and P ≤ 0.10 as a trend. PASW Statistics 18 was used for
the analyses. The power to detect a statistically signiﬁcant
diﬀerence (α ≤ 0.05) of 1.4 in the mean number of drugs
used by subjects with and without constipation was 80%.
2.5. Ethics. This study was approved by the Regional Com-
mittee for Medical and Health Research Ethics, Central
Norway, and by Privacy Ombudsman for Research at Oslo
University Hospital and performed in accordance with the
DeclarationofHelsinki.Allresidentsortheirnextofkingave
written informed consent to participate. Residents giving
consent themselves were informed by the nursing staﬀ.N e x t
of kin or legally acceptable representative to residents unable
to provide informed consent were given oral and written
information during a visit to the nursing home or by post
and phone before giving informed consent.
3. Results
Out of 24 invited nursing homes, 13 participated. In the par-
ticipating nursing homes, 267 out of 647 residents (41.3%)
participated in the study. Figure 1 shows the selection of
the subjects, and Tables 1 and 2 show the characteristics
of the residents and their use of drugs. The prevalence of
constipation was 71.5%. The mean number of drugs used by
the residents was 6.0 (SD 3.2, range 0–20); 17 (6.4%) used
drugs with markedly anticholinergic eﬀects.
Tables 1 and 2 also give comparisons between residents
withandwithoutconstipation.Neitheruseofdrugs,number
of drugs, nor use of drugs with anticholinergic eﬀects
was statistically signiﬁcantly associated with constipation.
Other antidepressants (N06AX) was signiﬁcantly associated
with constipation, and vitamin B12 (B03BA) and thyroid
hormones (H03AA) with less constipation.
Table 3 gives the independent predictors for constipation
(multivariable analyses). Neither number of drugs nor drugs
with anticholinergic eﬀect was signiﬁcantly associated with
constipation; drugs with anticholinergic eﬀect showed a
trend. Other antidepressants and benzodiazepine derivatives
(anxiolytics) (N05BA) were signiﬁcantly associated with
constipation;naturalopiumalkaloids(N02AA)andpropionic
acid derivatives (M01AE) showed a trend. Vitamin B12 and
thyroid hormones were associated with less constipation.
Analyses performed on original and imputed data did not
diﬀer in principal.
4. Discussion
Constipation was more prevalent in this study (71.5%)
than in most corresponding studies [4–6]. Comparisons ofGastroenterology Research and Practice 3
Table 1: Characteristics of the participants and comparisons between participants with and without constipation. The results are given as
mean (standard deviation (SD)), median (range), and number (proportion (%)).
Characteristics1 All participants
n = 267
Participants with
constipation
n = 191
Participants
without
constipation
n = 76
Statistics P value
Age (years) 85.4 (SD 7.1) 85.3 (SD 6.9) 85.6(SD 7.5) 0.69
Gender (female) 188 (70.4%) 139 (72.8%) 49 (64.5%) 0.19
Ability to give informed consent 98 (36.7%) 66 (34.6%) 32 (42.1%) 0.26
Functional constipation (Rome
III) (n = 266) 95 (35.7%) 95 (50.0%)2 0n . a .
Body mass index (kg/m2)
(n = 251) 25.5 (SD 4.9) 24.5 (SD 5.3) 24.7 (SD 4.9) 0.72
Smoking (n = 263) 19/49/195 13/30/144 6/19/51
Current/before/never (7.2/18.6/74.1%) (7.0/16.0/77.0%) (7.9/25.0/67.1%) 0.22
Use of alcohol > once a month
(n = 263) 39 (14.6%) 28 (14.9%) 11 (14.7%) 1.00
Walking steps/day (n = 184) 200 (0–5000) 139 (0–5000) 400 (0–5000) 0.02
Mobility 120/80/67 100/48/43 20/32/24
Bedridden/walk indoors/walk
outdoors (44.9/30.0/25.1%) (52.4/25.1/22.5%) (26.3/42.1/31.6%) <0.01
Intake of ﬂuids (Glass/day) 9.9 (SD 2.9) 9.0 (SD 2.8) 10.1 (SD 3.0) <0.01
Dietary ﬁbre (gram/day) 15.6 (SD 6.4) 15.3 (SD 6.3) 16.4 (SD 6.6) 0.18
Katz’ Activity of Daily Living 3
(n = 254) 2 (0–6) 1 (0–6) 3 (0–6) <0.001
Mini Nutritional Assessment score
(n = 197) 21.4 (SD 3.5) 19.6 (SD 3.9) 21.5 (SD 3.6) 0.001
Type of food (n = 266) 41/44/181 33/36/121 8/8/60
Mashed/without crust/ordinary
food (15.4/16.5/67.8%) (17.4/18.9/63.7%) (10.5/10.5/78.9%) 0.04
Incontinence urine only (n = 266) 93 (35.0%) 73 (38.2%) 20 (26.7%) 0.09
Incontinence urine and faeces
(n = 265) 124 (46.8%) 90 (47.4%) 34 (45.3%) 0.79
Bedsore/wound (n = 265) 32 (12.1%) 28 (14.7%) 4 (5.3%) 0.04
Number of diseases (n = 266) 5 (1–15) 5 (0–15) 5 (0–10) 0.85
Heart diseases (n = 265) 118 (44.5%) 82 (43.2%) 36 (48.0%) 0.50
Venous thrombosis, pulmonary
embolism (n = 264) 20 (7.6%) 17 (8.9%) 3 (4.1%) 0.21
Stroke (n = 264) 91 (34.5%) 72 (38.1%) 19 (25.3%) 0.06
Depression/anxiety (n = 266) 131 (49.2%) 100 (52.4%) 31 (41.3%) 0.13
Dementia (n = 265) 148 (55.8%) 105 (55.0%) 43 (58.1%) 0.68
Diabetes (both I and II) (n = 266) 32 (12.0%) 20 (10.5%) 12 (16.0%) 0.22
Parkinson’s disease (n = 266) 15 (5.6%) 10 (5.2%) 5 (6.7%) 0.77
Hypothyroidism (n = 266) 20 (7.5%) 9 (4.7%) 11 (6.7%) 0.001
S-creatinine (above reference
values) (n = 254) 62 (24.4%) 37 (20.4%) 25 (34.2%) 0.02
Albumin (g/L) (n = 167) 38.9 (SD 4.1) 38.5 (SD 4.2) 39.5 (SD 3.7) 0.16
1Number of residents is given in brackets when data are missing.
2Use of laxatives regularly is included in the deﬁnition of constipation.
3Katz Index of Independence in Activities of daily living. (Score 0–6: 0 = very dependent; 6 = independent).4 Gastroenterology Research and Practice
Participants with constipation
191/267 (71.5%)
29 wards with 647 residents
participated
13 nursing homes with 31 wards 
participated 
24 nursing homes in Oppland and 
Hedmark counties, Norway were invited
11 nursing homes were 
unwilling to participate 
Two wards were 
unwilling to participate
267 residents participated in the study 
380 residents were 
excluded:
Informed consent 
was not obtained 
Did not fulﬁl the 
inclusion/exclusion 
criteria
Severely ill 
Participants without constipation
76/267 (28.5%)
Figure 1: A ﬂow chart of the participants in the study.
prevalence rates are, however, diﬃcult because the deﬁni-
tions of constipation vary. In this study, a combination of
use of laxatives and the Rome III criteria for functional
constipation and constipation-predominant IBS was used.
Patients using laxatives regularly are supposed to have
constipation although they do not fulﬁl the Rome criteria,
and the two Rome III groups (functional constipation and
constipation-predominant IBS) are diﬃcult to distinguish in
subjects with reduced cognitive functions and are probably
notdistinctgroupsandcouldbemerged[22].Thisdeﬁnition
is sensible in this study population. The validity of the Rome
III criteria for constipation has, however, been questioned,
but no other instrument is available [23].
4.1. Drugs and Constipation. The main ﬁnding was that
use of drugs in general, including polypharmacy, was not
signiﬁcantly associated with constipation in this nursing
home population with a high prevalence of constipation and
polypharmacy. Most studies, reviews, and guidelines focus
on drugs and polypharmacy as risk factors for constipation
in elderly [4, 5, 7, 9, 14, 24].
The prevalence of use of drugs with markedly anti-
cholinergic eﬀect was three times higher in subjects with
constipationthaninthosewithout.Theconstipatingeﬀectof
drugs with anticholinergic eﬀect has been reported in several
studies and in reviews, and the nonsigniﬁcant ﬁnding in this
study is probably due to low power since rather few subjects
u s e dt h i st y p eo fd r u g s[ 4–7, 9, 25].
A few groups of drugs were associated with constipation.
Other antidepressants, which have also been associated with
constipation in other studies, and benzodiazepine derivatives
were signiﬁcantly associated with constipation [5, 26]. Pro-
pionic acid derivatives (M01AE) and natural opium alkaloids
(N02AA) showed a trend; the ORs were 7 and 5, respectively.
The high ORs show that the prevalence of constipation was
much higher in users than nonusers of these drugs and the
lackofstatisticalsigniﬁcancewasprobablyatypeIIerrordue
to few users. The constipating eﬀect of these drugs is known
from several studies and reviews [4, 5, 7, 9, 26].
To our knowledge, the signiﬁcant associations between
Thyroxin hormones and vitamin B12 and less constipation
have previously not been described. However, thyroxin has
been associated with diarrhoea [27].
4.2.OtherFactorsandConstipation. Reduced activity of daily
living was highly statistically signiﬁcantly associated with
constipation. Inactivity and dietary factors are explanations
of this association, which is reported also in other studies
and reviews [4, 5, 7, 9, 28]. The associations between both
diabetes and low intake of ﬂuids seen in this study have also
been reported in other studies [4, 5, 26, 28]. Constipation
was, as expected, somewhat higher in women than men
[1, 2, 26].
4.3. Strengths and Weaknesses. The participating rate was
lower than desired. Exclusion of 11 out of 24 nursing
homes probably occurred by chance. The low participation
rate in participating nursing homes (41.7%) might have
inﬂuenced the external validity. Informed consent was easier
to obtain from residents able to provide informed consent
themselves than from the next of kin. This might explain
why the prevalence of dementia was somewhat lower than
in some other studies. The most frail and dement residents
might therefore have been underrepresented [5, 6, 11, 12].
However, the prevalence of cardiac disease, cerebrovascular
disease, and depression were somewhat higher than reported
in other studies, indicating in all a representative sample [5,Gastroenterology Research and Practice 5
Table 2: Use of drugs by the participants and comparisons between participants with and without constipation. The results are given as
proportion (%) if not otherwise indicated.
Drugs All participants
n = 267
Participants with
constipation
n = 191
Participants
without
constipation
n = 76
Statistics P value
Use of drugs 98.5 98.4 98.7 1.00
Number of drugs (median with range) 6 (0–20) 6 (0–20) 6 (0–19) 0.90
Drugs with markedly anticholinergic eﬀect 6.4 7.9 2.6 0.17
Laxatives regularly only 61.0 85.3 01 —
Laxatives on demand only 5.2 0 18.4 —
Laxatives regularly and on demand 68.9 96.3 01 —
Contact laxatives (A06AB) 28.5 39.8 01 —
Osmotically acting laxatives (A06AD) 52.1 72.8 01 —
Enemas (A06AG) 4.9 6.8 01 —
Proton pump inhibitors (A02BC) 14.2 15.7 10.5 0.15
Insulin and analogues (A10A) 3.7 2.6 6.6 0.15
Potassium (A12BA) 7.9 7.9 7.9 1.00
Platelet aggregation inhibitors (B01AC) 39.7 41.4 35.5 0.41
Bivalent oral iron (B03AA) 13.9 14.7 11.8 0.70
Vitamin B12 (B03BA) 12.4 9.4 19.7 0.04
Organic nitrates (C01DA) 8.2 6.8 11.8 0.22
Sulphonamides, plain (diuretics) (C03CA) 36.0 37.2 32.9 0.57
Beta blocking agents, selective (C07AB) 17.2 15.2 22.4 0.21
Dihydropyridine derivatives (C08CA) 6.7 7.9 3.9 0.29
Angiotensin II antagonists2 (C09CA DA) 4.9 3.7 7.9 0.20
HMD-CoA reductase inhibitors (C10AA) 12.7 11.5 15.8 0.42
Thyroid hormones (H03AA) 9.7 6.8 17.1 0.02
Antibacterials—systemic use (J01) 15.0 14.1 17.1 0.57
Propionic acid derivatives (M01AE) 4.9 6.3 1.3 0.12
Bisphosphonates (M05BA) 6.4 6.8 5.3 0.79
Natural opium alkaloids (N02AA) 6.7 8.4 2.6 0.11
Phenylpiperidine derivatives (N02AB) 4.9 6.3 1.3 0.11
Other antiepileptics (N03AX) 4.1 4.7 2.6 0.73
Benzodiazepine derivatives (N05BA) 19.5 22.5 11.8 0.06
Benzodiazepine related drugs (N05CF) 29.2 30.9 25.0 0.37
SSRI3 (N06AB) 31.5 30.4 34.2 0.56
Other antidepressants (N06AX) 15.7 18.8 7.9 0.03
Anticholinesterases (N06DA) 6.7 4.7 11.8 0.06
Phenothiazine derivatives (R06AD) 5.2 5.2 5.3 1.00
1Use of laxatives regularly is included in the deﬁnition of constipation.
2Both plain and in combination with diuretics.
3Selective serotonin reuptake inhibitors.
6,12].Thedeﬁnitionofconstipation,whichincludedregular
use of laxatives, might contribute to the high prevalence of
constipation[5,6,11,12].Subjectsonregularuseoflaxatives
probably have constipation when treatment is stopped, but it
couldnotberuledoutthatsomepatientscontinuetreatment
after ended indication. Despite these limitations, the external
validity is judged as satisfactory since all other variables (age,
sex, mobility, etc.) were within the range described in other
studies [5, 6, 11, 12].
More information than normally in clinical studies was
based on information from the nurses, next of kin and the
medical journals, and less from the residents themselves,
since the majority of the participants had cognitive impair-
ment. This might have reduced the validity of the data, but
use of deputies was inevitable.
Groups of drugs were analyzed at ATC-level 4, which
are drugs with similar chemical structure and uniform side
eﬀects. Analyses on ATC-level 5 would have resulted in too6 Gastroenterology Research and Practice
Table 3: Variables associated with constipation. The analyses were performed with either number of drugs (Analysis 1), anticholinergic
eﬀect (Analysis 2), or groups of drugs (Analysis 3) as independent variables in backward logistic regression analyses.
Independent variables
Constipation
Analysis 1 Analysis 2 Analysis 3
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Number of drugs1 1.04 (0.94–1.15) 0.43
Drugs with markedly
anticholinergic eﬀect1
(n = 17)
3.69 (0.78–17.53) 0.10
Benzodiazepine derivatives
(N05BA) (n = 53)
2.80 (1.12–7.04) 0.03
Other antidepressants
(N06AX) (n = 42)
3.07 (1.09–8.68) 0.03
Vitamin B12 (B03BA)
(n = 33)
0.39 (0.16–0.93) 0.03
Levothyroxine sodium
(H03AA) (n = 26)
0.27 (0.10–0.72) 0.01
Propionic acid derivatives
(M01AE) (n = 13)
7.00 (0.75–65.08) 0.09
Natural opium alkaloids
(N02AA) (n = 17)
5.00 (0.95–25.94) 0.06
Age1 1.00 (0.95–1.05) 0.94 0.99 (0.95–1.04) 0.70 1.01 (0.96–1.06) 0.78
Gender (female)1 1.66 (0.86–3.21) 0.13 1.53 (0.81–2.91) 0.19 1.80 (0.89–3.61) 0.10
Activity of daily living 0.73 (0.63–0.85) <0.001 0.72 (0.63–0.84) <0.001 0.71 (0.60–0.84) <0.001
Intake of ﬂuids (glass/day) — — — — 0.90 (0.81–1.01) 0.07
Hypothyroidism (n = 20) 0.19 (0.07–0.56) <0.01 0.26 (0.09–0.71) <0.01 — —
Diabetes (n = 266) — — — — 0.35 (0.14–0.88) 0.02
S-creatinine2(n = 254) 0 . 5 4 ( 0 . 2 7 – 1 . 1 0 ) 0 . 0 9 ————
Age and gender have been included in all analyses regardless of signiﬁcance. 1Number of drugs and anticholinergic eﬀect have been included in the respective
analyses regardless of signiﬁcance. 2Serum Creatinine above reference values (90 and 105μmol/L for women and men, resp.). —Has not been included in the
ﬁnal analyses.
smallgroups, andATC-level 3, orhighercombine drugs with
diﬀerent side eﬀects.
Thepowerofthestudyallowstheexclusionofaneﬀectof
drugs in general, including polypharmacy, on constipation.
The study also indicates an unfavourable eﬀect of drugs with
markedly anticholinergic eﬀects (OR 3.7). Some associations
between groups of drugs and constipation with high OR but
not statistically signiﬁcant associations (P = 0.05–0.10) have
been reported because the associations might be of clinical
signiﬁcance,and thelackof statisticallysigniﬁcancemight be
duetolowpower(fewusersofthesedrugs).Theconstipating
eﬀect of some groups of drugs used by few subjects might
have been missed.
5. Conclusion
Use of drugs in general, including polypharmacy, was not
associated with constipation in elderly in nursing homes,
but some speciﬁc groups of drugs were. Therefore, in elderly
with constipation, focus should be on speciﬁc groups of
drugs and not drugs in general. This study indicated that
focus should be on benzodiazepine derivatives, other antide-
pressants, natural opium alkaloid, propionic acid derivatives,
and drugs with markedly anticholinergic eﬀects, in addition
to nonpharmacological interventions like activity of daily
living.
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